News
Before Novo Nordisk acquired Dicerna Pharma, that company was a partner in the R&D of drugs for metabolic disorders. The relationship began in 2019, with Novo Nordisk committing $225 million in ...
The Lexington site, which also consists of 33 and 75 Hayden Ave., includes Dicerna Therapeutics, a Novo Nordisk subsidiary focused on RNA interference (RNAi) drug development.
Novo Nordisk’s RNA strategy was kick-started by its $3.3 billion buyout of RNAi partner Dicerna Pharmaceuticals in late 2021 as part of the Big Pharma’s search for new growth drivers. As well ...
With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam - Fierce Pharma
Novo Nordisk has spent the last few years grappling with the. ... The Danish drugmaker got its hands on the therapy with its 2021 purchase of Dicerna Pharmaceuticals for $3.3 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback